Alkermes
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.About ALKS
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.
ALKS Key Statistics
Stock Snapshot
As of today, Alkermes(ALKS) shares are valued at $29.15. The company's market cap stands at 4.82B, with a P/E ratio of 14.65.
During the trading session on 2026-01-14, Alkermes(ALKS) shares reached a daily high of $29.80 and a low of $28.93. At a current price of $29.15, the stock is +0.8% higher than the low and still -2.2% under the high.
Trading activity shows a volume of 2.08M, compared to an average daily volume of 1.86M.
The stock's 52-week range extends from a low of $25.17 to a high of $36.45.
The stock's 52-week range extends from a low of $25.17 to a high of $36.45.
ALKS News
Avadel Pharmaceuticals (AVDL) announced that, in relation to the previously announced offer for the company by Alkermes (ALKS), pursuant to which Alkermes will...
Claim 70% Off TipRanks Premium An announcement from Alkermes ( (ALKS) ) is now available. In 2025, Alkermes generated more than $1.45 billion in commercial re...
Alkermes (ALKS) shares are in focus after the U.S. FDA granted Breakthrough Therapy designation to alixorexton for narcolepsy type 1, based on phase 1 and Vibra...
Analyst ratings
81%
of 16 ratingsMore ALKS News
Alkermes (ALKS) announced that the FDA has granted Breakthrough Therapy Designation to alixorexton, a novel, investigational, and oral orexin 2 receptor agonist...
In trading on Wednesday, shares of Alkermes plc (Symbol: ALKS) crossed above their 200 day moving average of $25.61, changing hands as high as $25.85 per share....